What prompted Waters to go in for this acquisition?
There are many reasons, but three stand out. Chief among them is a common mission that we share to help lower the costs and increase access to biotherapies. Biologies, including cell and gene therapies, can dramatically change the quality of life for a significant percentage of the population and there is considerable demand for developing these drugs. But the astronomical costs of delivering these therapies are a major barrier to adoption.
Wyatt's innovative products are used to determine the properties of novel therapeutics such as cell and gene therapies, vaccines and proteins, as well as synthetic polymers and nanoparticles. This is complementary to the work we already do in the large molecule separation and characterisation space. We believe that combining our capabilities with Wyatt's, a company with robust exposure to bioanalytical characterisation, can help our customers to lower the costs of biologic drug development and manufacturing. That, in turn, can help increase patient access and affordability of these life-changing therapies. Second, bioanalytical characterisation for new modalities is a significant market opportunity, with a $1.8 billion total addressable market and 10-12 per cent projected annual growth. With our joint efforts, we are well positioned to build a high-growth bioanalytical characterisation business.
Finally, this acquisition adds significant value for our shareholders. Wyatt is immediately accretive to Waters' revenue growth and margin profile. But it is more than the profit for us - the long-term potential to help our biopharma customers develop and bring to market life-saving therapies at a lower cost is solving a problem that truly matters.
How would you describe the benefits of Wyatt's light scattering technologies?
Esta historia es de la edición July 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición July 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.